cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Cerebrospinal Fluid Flow in Adolescent Idiopathic Scoliosis

Adolescent Idiopathic Scoliosis (AIS) is the most frequent spinal deformity in adolescence, but its etiology remains unknown. Recent publications suggest a link between ciliopathy and AIS. More specifically a modification of the cerebro-spinal fluid (CSF) flow by ciliary dysfunction could be at the origin of a scoliotic deformity.

This study aims to compare the CSF flow measured by magnetic resonance imaging (MRI) in an AIS group and a control group.


Eligibility Criteria:
Common Inclusion Criteria for the 2 groups :

* Female subject aged 12 to \< 18 years old
* Affiliated to the French social security system
* Having signed the inform consent form
* Whose parents have given their consent

Additional Inclusion Criteria for the AIS group:

* Subject with right thoracic AIS defined by the existence of a 3D spine deformation with a frontal deviation to right dorsal convexity with a Cobb angle of at least 20°, and a rotation of at least 20°, as evidenced by the presence of a vertebral gibbosity ≥ 5° at the Bunnel scoliometer.

If the scoliosis has more than one curvature, the right chest curvature should be the greatest high (highest frontal Cobb angle)

* Subject with x-rays of total spine, face and profile under load, according to the EOS technique, dating from less than 3 months.

Common Exclusion Criteria for the 2 groups:

* Instability to submit to the medical follow-up of the study for psychic, social or geographical reasons
* At least 6 "cafe au lait" spots with a size ≥ 1.5 cm (may be suggestive of neurofibromatosis)
* Ligament hyperlaxity confirmed by a Beighton score \>4/9 (which may be suggestive of scoliosis secondary)
* Contraindications of a cerebro-medullary MRI: claustrophobia, foreign bodies, and ferrometallic clips of the trunk or cephalic segment, cochlear implants, stimulators and implantable cardiac defibrillators, insulin pump
* Inequality in length of the lower limbs ≥ 20 mm on clinical examination
* Subject presenting neurological signs (signs of pyramidal irritation, sensory-motor deficit, clinical signs suggestive of cerebellar pathology ...)
* Known vestibular pathology
* Taking psychotropic drugs

Additional exclusion criterion for the AIS group:

* Subject with secondary scoliosis : neurological, orthopedic, malformative...

Additional criteria for the control group:

* Subject with a scoliosis angle ≥ 10° on a photogrammetric screening assessment (optical process, non-irradiating, which allows an Morphometric evaluation of the trunk in 3D, thanks to the analysis of the trunk reliefs)
* Subject whose clinical examination shows a gibbosity measurable (\>5°) with the scoliometer of Bunnel
The Ventilation During In-hospital Cardiac Arrest Study

The goal of this prospective observational study is to learn how ventilation quality parameters during cardiopulmonary resuscitation (CPR) are associated with short-term survival following in-hospital cardiac arrest of adult patients.

The main questions it aims to answer are:

What ventilation volume during CPR is associated with the highest chance of return of spontaneous circulation (ROSC)? What ventilation rate during CPR is associated with the highest chance of ROSC?

Researchers will compare different levels of ventilation rates and volumes that are blindly measured during CPR to see how the observed rates and volumes are associated with survival outcomes and complications.


Eligibility Criteria:
Inclusion Criteria:

1. In-hospital cardiac arrest
2. Age ≥ 18 years
3. \>1minute of recorded ventilation data

Exclusion Criteria:

1. Documented do-not-attempt cardiopulmonary resuscitation order
2. Invasive mechanical circulatory support at the time of the cardiac arrest
Systemic Vitamin D Supplementation in Dental Implants Patients

Vitamin D plays an essential role in calcium homeostasis and is critical for bone formation and remodeling.

Evidence has demonstrated that vitamin D deficiency plays an important role in dental implants outcomes.

Low serum levels of Vitamin D is considered as a risk factor, not only for low mineral bone density but also in other metabolic pathways such as those involved in immune response and chronic inflammatory diseases.

There are few studies demonstrating the role that vitamin D deficiency in the etiopathogenesis of oral diseases and the consequences in Dental Implants.

Dentists have not yet well understood the importance of a good bone metabolism response for a successful bone regeneration and osseointegration of implants.

An insufficient bone response can not guarantee the necessary stability of the implants placed in it, has been one of the biggest problems of implantology.

Thus, the aim of this study is to evaluate the efficacy of Systemic vitamin D supplementation in menopausal women cadidates for dental implants.

Eligibility Criteria:
Inclusion Criteria:

- Menopause patients

Exclusion Criteria:

* patients with a past history of neurological disorder;
* who had received pharmacotherapy for depression within 8 weeks of screening;
* who were taking medication known to interfere with Vit D;
* who had recent psychiatricor systemic illness;
* uncontrolled hypertension (blood pressure \> 160/95mmHg);
* unstable cardiovascular disease;
* User of psychoactive medications;
* alcohol excess consumption abuse.
Treatment in Right Colon Diverticulitis Patients

The right colon diverticula, unlike those in the left colon, contain all layers of the colon and is called the true diverticulum. Perforation is observed less frequently due to its full thickness. Conservative treatment can be applied unless complications such as abscess formation and free perforation occur. Unlike the left, right colon diverticulitis has low complications and can be treated conservatively. The differential diagnosis of right colon diverticulitis should be kept in mind in order to prevent unnecessary surgeries. Surgical treatment is inevitable in cases such as recurrent diverticulitis, generalized peritonitis, and suspected malignancy.

The right colon diverticula, unlike those in the left colon, contain all layers of the colon and is called the true diverticulum. Perforation is observed less frequently due to its full thickness. Conservative treatment can be applied unless complications such as abscess formation and free perforation occur. Here, we aimed to discuss the results of conservative and surgical treatment for right colon diverticulitis in the light of the literature. 150 patients treated for colon diverticulitis between 2015-2020 were retrospectively screened. Right colon diverticulitis detected incidentally, missing data, and left colon diverticulitis were excluded from the study. Data of a total of 26 patients were accessed. Unlike the left, right colon diverticulitis has low complications and can be treated conservatively. The differential diagnosis of right colon diverticulitis should be kept in mind in order to prevent unnecessary surgeries. Surgical treatment is inevitable in cases such as recurrent diverticulitis, generalized peritonitis, and suspected malignancy

Eligibility Criteria:
Inclusion Criteria:

* diagnosed with right colon diverticulitis

Exclusion Criteria:

* Left colon diverticulitis
* Right colon diverticulitis detected incidentally
* lacking data
Predicting Analgesic Response to Acupuncture: A Practical Approach

In this placebo controlled, patient and assessor blinded clinical trial, the investigators will administer electroacupuncture vs sham electroacupuncture to patients suffering from chronic low back pain, and monitor their symptoms as well as collecting objective outcome measures. The investigators objective is to identify predictors of pain reduction and functional improvement with electroacupuncture vs placebo.


Eligibility Criteria:
Inclusion Criteria:

1. Age 21-65
2. English Fluency
3. Chronic LBP for ≥ 6 Months

   1. Chronicity: cLBP "defined as a back pain problem that has persisted at least 3 months and has resulted in pain on at least half the days in the past 6 months."
   2. Location: "between the lower posterior margin of the rib cage and the horizontal gluteal fold
4. Average pain over the last month ≥ 5/10

Exclusion Criteria:

1. Radicular low back pain: defined as sharp (or burning) pain, with a defined territory, radiating down the limb, beyond the knee. Radicular pain may be accompanied by sensory and motor deficit along 1 or more dermatomes. Radicular back pain may also be accompanied by MRI evidence of intervertebral disc protrusion and compression of spinal cord and/or nerve roots.
2. Pending litigation or Worker's compensation related to the low back pain.
3. Currently pregnant or planning to become pregnant (in next 6 months)
4. American Society of Anesthesiologist (ASA) class III or above physical status. ASA class III is defined as "a patient with severe systemic disease." Examples would include poorly controlled diabetes, hypertension, COPD or morbid obesity (BMI ≥ 40).
5. Mental health conditions or treatment for mental health problems that would interfere with study procedures, at the discretion of the study team. For example, psychosis, untreated major depression, ongoing substance abuse, suicidal ideation. These will be assessed by the MINI.
6. Medications: opioids ≥60mg morphine equivalent units/day, benzodiazepines, corticosteroids.
7. Prohibited interventions: during the study period, the following are not permitted

   1. Back surgeries
   2. Injections with local anesthetics or steroids to the back
   3. New chiropractic maneuvers
   4. New physical therapy programs
   5. New medications for back pain
8. Bleeding disorders at the discretion of the study team.
9. Previous acupuncture treatment in the past 10 years.
10. Medical conditions that would interfere with study procedures (eg. Heart disease or pacemaker, active infection), per discretion of the team
A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

This trial is conducted to evaluate the safety of a study drug given by injection under the skin to healthy participants and participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. Information about any side effects and tolerability will be documented. This study is approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.


Eligibility Criteria:
Inclusion Criteria:

For all study participants:

* Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes for at least 1 year
* Male participants with female partners who can become pregnant must agree to use an effective method of birth control during the study and for 4 months after study drug dosing
* Have a body mass index (BMI) of greater than 18.5 kilogram per square meter (kg/m²) and less than or equal to 35 kg/m² at screening
* Have blood pressure, pulse rate, blood and urine laboratory test results acceptable for the study
* Have venous access sufficient to allow blood sampling

For participants with Type 2 Diabetes Mellitus (T2DM):

* Have T2DM controlled with diet and exercise alone or are stable on metformin for at least 30 days
* If taken, prescription medications for medical conditions (e.g.antihypertensive agents, aspirin or lipid lowering agents) are stable for at least 4 weeks
* Have a hemoglobin A1c (HbA1c) greater than or equal to 7.0% and less than or equal to 9.5%

Exclusion Criteria:

For all study participants:

* Are currently participating in another clinical study
* Have a history of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
* Have or used to have health problems or laboratory test results or electrocardiogram (ECG) readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study
* Have donated blood or have had a loss of 500 milliliters (mL) or more in the last 3 months or have had any blood donation within the last month from screening
* Intend to start any new over-the-counter or prescription medications 7 and 14 days before planned dosing

For participants with T2DM:

* Have taken any glucose-lowering medications, other than metformin, including insulin, in the past 3 months before screening
* Have had more than 1 episode of severe hypoglycemia, within 6 months before entry into the study, or have a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
* Have had a blood transfusion or severe blood loss in the past 3 months, or any blood disorder that could interfere with the understanding of the results of the study
* Have received chronic (lasting greater than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, and inhaled preparations) in the 3 past months, or have received any glucocorticoid therapy within 30 days before screening
Quantifying Fatigue in Cancer Patients Using Smart Bracelet Devices

This project expects to enroll 60 cancer patients, 60 healthy people and their subjective-objective measurements on fatigue, stress, and total steps will be validated so that the information can be used in further care and improvement of life of quality of the patients.


Eligibility Criteria:
Inclusion Criteria:

* Age ≧ 20 years old;
* One group had a cancer diagnosis, one group no cancer diagnosis;
* Can continuous wearing bracelet for 5 days or more

Exclusion Criteria:

* Unclear and unable to answer the questionnaire
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

The main aim of this study is to learn if velaglucerase alfa (VPRIV) improves growth and symptoms in participants up to 5 years of age with Gaucher disease. Symptoms will be checked with blood tests.

This study is about collecting data available in the participant's medical record as well as data from each participant's ongoing treatment. No study medicines will be provided to participants in this study. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.

When the participants start the study, they will visit the study clinic every 6 months after their first visit.


Eligibility Criteria:
Inclusion Criteria:

* The participant's caregiver is able and willing to provide informed consent.
* The participant is male or female younger than or equal to 4 years of age at treatment initiation.
* The participant has received and confirmed a current diagnosis of GD type 1 or type 3 (biochemically and/or genetically).
* The participant has been receiving intravenous (IV) Velaglucerase alfa treatment for GD.
* In the opinion of the investigator, the participant's caregiver is capable of understanding and complying with protocol requirements.
* The participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

* The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., child, sibling) or may consent under duress.
* The participant is judged by the investigator as being ineligible for any other reason.
Paracetamol Compared With Ketorolac for Post-operative Analgetic

Post-operative analgetic modalities vary between center to center, especially in Indonesia. Considerations include potency/effectivity of the analgetics to achieve adequate pain control as soon as possible, reducing the total opioid dose intake and overall reducing potential opioid adverse effects. NSAID have been known to have more adverse effects than acetaminophen (paracetamol) but offers a higher potency for analgetic effects. Here the investigators compare whether paracetamol is adequate as a post-operative analgetics and confers fewer overall adverse effects when compared with ketorolac (NSAID)

OBJECTIVE: The purpose of this study was to compare the efficacy of Ketorolac versus Paracetamol as an adjunct to Nalbuphine in the management of post-operative pain following elective cardiac surgery.

STUDY DESIGN: Randomized (single-blind) control trial.

SAMPLING TECHNIQUE: Computer generated, randomized selection of patients with 50% probability of assignment into either group.

PLACE AND STUDY DURATION: (single center) PICU and Neurosurgery HCU at the Cipto Mangunkusumo National Referral Center Hospital, Jakarat, Indonesia, over a period of 6 months, from March to August 2022.

METHODS: Eighty-five patients (46 in paracetamol group and 39 in ketorolac group) were randomly assigned to receive either Paracetamol (treatment) or Ketorolac (control), along with the usual pre and intraoperative sedative/analgetics, and opioid as indicated over the first 48 hours postoperatively. The treatment group received injection Paracetamol 15mg/kg six hourly, whereas control group received injection Ketorolac 0.5mg/kg eight hourly.

PRIMARY OUTCOME: The rFLACC (pain score) was evaluated at 0, 8, 12, 24 and 48 hours post-operation and a score of 4 or less was taken as a cut-off for adequate pain control.

SECONDARY OUTCOMES: The total dose of opioid administered to each patient and adverse effects

Eligibility Criteria:
Inclusion Criteria:

* Postoperative patients admitted to Neurosurgery HCU or PICU
* Parents/guardian signed informed consent forms

Exclusion Criteria:

* History of allergy to paracetamol and ketorolac
* Administration of opioid 24 hours before surgery
* Liver dysfunction
* Renal failure
When to Apply to Which Patient in MSC?

Mesenchymal stem cell (MSC) therapy is among the promising treatments for acute respiratory distress syndrome (ARDS). Our study aimed to investigate the clinical efficacy of MSC treatment in COVID-19 patients, to determine when this treatment can be applied to which patient, and to evaluate its contribution to prognosis.

The study was conducted retrospectively in patients diagnosis of COVID-19 in the intensive care units. Patients with severe ARDS \[partial pressure of arterial blood oxygen and inhaled oxygen fraction (PaO2: FiO2) ratio of 100 or less\] were included in the study. Demographic data of the patients (gender, age), comorbidities (hypertension, coronary heart disease, diabetes, cerebrovascular diseases, hepatitis B infection, cancer, chronic kidney disease, and immunodeficiency), Charlson comorbidity index (CMI), date of diagnosis, date of admission to the hospital, date of admission to the ICU, Acute Physiology And Chronic Health Evaluation (APACHE) II score, presence of high flow nasal oxygen (HFNO) or mechanical ventilator (MV) support, laboratory findings (blood cell count, blood biochemistry, hepatorenal function, coagulation function, D-dimer, C-reactive protein (CRP), procalcitonin, ferritin, arterial blood gas analysis) before (day 0) and after MSC application, on 3rd and 7th days, partial oxygen/fractionated oxygen (Pa/Fi) ratio, discharge or death information, and attributed causes of death were recorded on the study form. Pa/Fi ratio was calculated with the formula (oxygen dissolved in arterial blood gas / oxygen liter given to the patient).

Eligibility Criteria:
Inclusion Criteria:

* Patients who were followed up and treated after being admitted to the Intensive Care Unit after March 2020
* Patients with COVID PCR +
* Typical or suspected cases of Thorax BT COVID
* Cases over the age of 18.

Exclusion Criteria:

* Those with a contraindicated condition (cancer disease, allergy) for MSC application
* Those who are endotracheal intubated during the application and are connected to a respirator
* Those who died in the first 24 hours after the application
* Cases that are not positive or suspicious for COVID.
* Cases under the age of 18.
* Cases where patient data could not be reached.
Early Sleep Apnea Termination Using Sound Stimulation

Current evidence suggest that sleep apnea-associated oxygen desaturations may induce cardiovascular morbidities in the long term, whereas arousals associated with sleep apneas seem to induce mainly transient nocturnal hypertension. Reducing the occurrence and the magnitude of sleep apnea-associated oxygen desaturations could therefore have a beneficial effect on sleep apnea-associated comobidities. Since sleep apneas usually end with an arousal allowing pharyngeal muscles reactivation, a treatment option could consist of generating an early short awakening to anticipate apnea termination and decrease the risk of oxygen desaturation. The aim of this study is thus to determine if an early sleep apnea termination through the emission of a sound can achieve lower oxygen desaturations compared with "untreated" sleep apneas.

The aim of the study is to determine the effect of short sound stimulations on sleep apnea associated desaturations

20 OSA subjects will be recruited and studied with polysomnography and a head band allowing to emit short sound stimulations during sleep. the study will take nplace at the Center for investigation and research in sleep (CIRS)

The magnitude of oxygen desaturations following apnea with and without sound stimulations will be compared. The effects of different types of sound stimulations on the magnitude of cortical and autonomic reactions will also be studied as well as the patients' subjective perception of the sounds.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Able to give informed consent as documented by signature
* Apnea / hypopnea index \> 30 / h (severe)
* Obstructive Apnea Index \> 15 / h
* Mean amplitude of desaturations (during diagnostic night) ≥ 5%

Exclusion Criteria:

* Perception deafness
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.,
* Professional drivers
Development of Endoscopic Treatment for Achalasia

Per Oral Endoscopic Myotomy (POEM); comparison of two surgical techniques division all the esophageal muscle layers versus division the inner circular muscle layer of the esophagus only.

Prior to surgery, all patients undergo upper endoscopy , x-ray "time barium" manometry, 24 hours pH registration. Moreover Quality of Life instrument (RAND-36), GSRS (Gastrointestinal Symptom Rating Scale) and a dysphagia score (Eckardt score) are completed by all patients.

Follow-up with surveys 3, 6, 12, and 36 months (GSRS, RAND-36 and Eckardt score).

At 3,12 and 36 months an x-ray "time barium" is performed and after 12 months a gastroscopy and at 24 hours esophageal pH monitoring are performed.

Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed achalasia
* the patient should understand the nature and the purpose of the study and give informed consent

Exclusion Criteria:

* previous surgical treatment of achalasia
* inability to understand the contents of or follow the protocol
* other pathology as an explanation for the obstruction of the esophageal transition
The Copmparison of Accuracy of PtcCO2 and in PetCO2 in COPD Patients

The pathophysiological characteristics of COPD is irreversible airflow restriction which may influence the gas exchange and cause the abnormal PaO2 and PaCO2. Assessment of the partial arterial pressure of carbon dioxide (PaCO2 ) is the 'gold standard' for the evaluation of the adequacy of alveolar ventilation.Method used mostly nowadays : arterial puncture which is accurate but is invasive 、painful、 non-dynamic and there is risk of infection and tissue、nerve damage. Noninvasive measurement methods (Most commonly used)： end-tidal CO2（ ETCO2）、 transcutaneous CO2(TcCO2). They all can monitor the PaCO2 dynamically、 noninvasively, but is existence of controversy of the accuracy. So the investigators want to compare the accuracy of these two noninvasive methods for assessment of PaCO2.


Eligibility Criteria:
Inclusion Criteria:

* COPD patients

Exclusion Criteria:

* hemodynamics is unstable;
* any other lung disease despite COPD；
* other diseases influencing experiments: Cognitive impairment disease、 mouth and nose trauma.